A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments. GLY-LOW supplementation reduced caloric intake and increased insulin sensitivity in mice. In female mice, GLY-LOW supplementation reversed aging-related declines in female hormones. Studies in humans are needed to examine the feasibility, utility and efficacy of GLY-LOW supplementation in post-menopausal women with obesity toward improving aging-related impairments. The effect of GLY-LOW supplementation on these obesity and biological age-related impairments in post-menopausal adult female humans with obesity is unknown. We aim to translate the findings of GLY-LOW supplementation in animals to a cohort of healthy, postmenopausal females at birth with obesity by conducting a one-group, no-placebo comparer, pre post intervention clinical trial. Additionally, we propose to examine the specific effect of supplementation by GLY-LOW on biological aging via retina scan. The objectives of the proposed pilot study are: I. Conduct a 6-month pilot study to examine the feasibility, utility and efficacy of GLY-LOW supplementation in a total of 40 postmenopausal female born adults \> 55 years with obesity (≥ 30 BMI).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Insulin Resistance (IR)
Timeframe: During the screening/baseline visit and again during the 6-month follow-up visit.
Fasting Insulin (I) and Glucose (G)
Timeframe: During the screening/baseline visit and again during the 6-month follow-up visit.
Glycosylated Hemoglobin [Hemoglobin A1C (HBA1C)]
Timeframe: During the screening/baseline visit and again during the 6-month follow-up visit.
BMI [weight (kg) divided by height (m2)]
Timeframe: During the screening/baseline visit and again during the 6-month follow-up visit.
Body Composition [lean mass, fat mass, bone density and area, central adiposity (DEXA); waist circumference]
Timeframe: During the screening/baseline visit and again during the 6-month follow-up visit.